Biopharmaceutical company UroGen Pharma Ltd. (URGN) said Thursday that the Phase 2 APOLLO clinical trial of a RTGel hydrogel formulation in combination with Botox (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder (OAB) and urinary incontinence did not meet the primary endpoint of the trial.
from RTT - Biotech https://ift.tt/2EzcnRT
via IFTTT
No comments:
Post a Comment